ORALTAG (iohexol) by R-Pharm US is x-ray contrast activity [moa]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
ORALTAG is an oral iohexol solution approved by the FDA in 2015 as an X-ray contrast agent for diagnostic imaging procedures. Iohexol functions as a radiopaque medium that enhances visualization of internal structures during radiographic examinations. The product is used in diagnostic imaging to improve contrast and clarity of anatomical regions under X-ray.
Product is at peak lifecycle stage with moderate competitive pressure (30/100), indicating stable but not hypergrowth commercial environment with established team structures.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Worked on ORALTAG at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ORALTAG is a mature diagnostic imaging product with zero linked job postings, indicating limited dedicated hiring momentum. Career opportunities on this product are primarily in established commercial roles focused on market maintenance rather than rapid expansion.